CorMedix Inc (NASDAQ:CRMD) Stock Now Rated "Moderate Buy" by Wall Street Analysts
Wall Street analysts have given CorMedix Inc (NASDAQ:CRMD) a "Moderate Buy" consensus rating, with seven out of nine analysts recommending a buy and two a hold. The average 12-month price target is set at $15.00, significantly higher than its opening price of $7.19. This positive outlook follows CorMedix exceeding its quarterly earnings and revenue estimates, alongside increased institutional investment, including a substantial new position taken by BlackRock Inc.
150,656 Shares in CorMedix Inc $CRMD Acquired by Bank of America Corp DE
Bank of America Corp DE has acquired 150,656 shares of CorMedix Inc (NASDAQ:CRMD) in the second quarter, valuing its new position at approximately $1.18 million and giving it a 0.19% stake in the company. Other institutional investors like BlackRock Inc., Pacer Advisors Inc., and Bank of New York Mellon Corp also adjusted their holdings. Analysts maintain a "Moderate Buy" rating for CorMedix with a consensus price target of $15.00, following strong Q2 earnings that surpassed estimates.
CorMedix Inc. R (19KA.F) Q1 FY2026 earnings call transcript
CorMedix Inc. reported strong Q1 2026 results with net revenue of $127.4M, a significant increase from the previous year, driven by DefenCath growth and the Melinta acquisition. The company raised its full-year revenue guidance to $325M-$345M and adjusted EBITDA to $115M-$135M, reflecting robust demand and operational efficiency. CorMedix also highlighted positive Phase III results for REZZAYO in its late-stage pipeline.
Diluted net income available to common stockholders of CorMedix Inc. – HAN:19KA
This article provides financial information for CorMedix Inc. (19KA) on the Hannover Stock Exchange, specifically focusing on its diluted net income available to common stockholders. It presents a period value and details any changes and percentage changes, indicating that the data is generated by humans and sourced from ICE Data Services and FactSet.
Non-operating income (total) of CorMedix Inc. – HAN:19KA
This article focuses on the non-operating income of CorMedix Inc. (HAN:19KA) on the Hannover Stock Exchange. It appears to be a financial data page from TradingView, indicating that specific financial figures for non-operating income would be presented here, though the actual data is not displayed in the provided content. The page also includes various navigation and information links typical of a financial data platform.
CorMedix Inc. Revenue Breakdown – HAN:19KA
CorMedix Inc. generated 265.39 million EUR in revenue last year, with its Drug segment being the top performer, contributing 259.12 million EUR. The United States was the primary geographic contributor, also accounting for 259.12 million EUR of the company's revenue. This marks a significant increase from the previous year's figures in both categories.
Price to cash flow ratio of CorMedix Inc. – HAN:19KA
This article provides financial information for CorMedix Inc. (HAN:19KA) on the Hannover Stock Exchange, specifically focusing on its price-to-cash-flow ratio. It indicates that the market is closed and no trades have occurred for this stock.
Form 4 CorMedix Inc For: 27 September
This article reports on a Form 4 filing for CorMedix Inc. on September 27. It briefly mentions the company's stock symbol CRMD and a recent price movement of -3.64%. The article provides no further details regarding the content of the Form 4.
Form 4 CorMedix Inc For: 27 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for CorMedix Inc. related to activity on September 27. It provides the title of the SEC filing and notes that the information is presented by Investing.com, a financial markets news service. The content is brief, primarily serving as an announcement of the regulatory filing.
Form 4 CorMedix Inc For: 27 September By Investing.com
This article reports on a Form 4 filing by CorMedix Inc. for September 27. It notes that CRMD's stock gained 1.03%. The content is brief and primarily serves as an announcement for the filing.
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix (CRMD) has shown significant growth in revenue, driven by DefenCath and the acquisition of Melinta, and possesses strong liquidity. However, its earnings visibility is limited due to upcoming changes in DefenCath reimbursement and increased operating costs as the company expands and integrates new acquisitions. While the company has commercial traction, a "Hold" rating is suggested as it navigates these challenges.
Cormedix Inc Lobbying Profile, 2015
This article provides a lobbying profile for Cormedix Inc. in 2015, detailing their federal lobbying efforts. As of July 23, 2026, Cormedix Inc. spent $380,000 on direct federal lobbying for the 2026 period (January 1 - June 30). The information is based on OpenSecrets' calculations using data from the Senate Office of Public Records.
CorMedix Inc (CRMD) Stock Price Target & Forecast
CorMedix Inc (CRMD) has a consensus analyst price target of $15.33, representing a potential upside of 95.33% from its current price of $7.85. Based on ratings from 6 analysts, CRMD receives a "Buy" recommendation, with 4 Strong Buy ratings and 2 Buy ratings in the current month. The company's EPS is projected to be -0.101 in FY2026Q3, following a reported EPS of 0.331 in FY2026Q2.
Oppenheimer initiates CorMedix stock coverage with outperform rating
Oppenheimer initiated coverage on CorMedix Inc. (NASDAQ:CRMD) with an Outperform rating and a $15.00 price target, significantly higher than its current trading price of $7.78. The firm believes investors are underestimating the potential of DefenCath, the diversified Melinta portfolio, and Rezzayo prophylaxis optionality. CorMedix also reported strong Q2 2026 results, exceeding expectations with earnings of $0.29 per share and revenue of $101.9 million.
Oppenheimer Initiates CorMedix at Outperform With $15 Price Target
Oppenheimer has initiated coverage on CorMedix with an Outperform rating and a $15 price target. This reflects a positive outlook on the company's prospects.
CorMedix (NASDAQ:CRMD) Coverage Initiated by Analysts at Oppenheimer
Oppenheimer has initiated coverage on CorMedix (NASDAQ:CRMD) with an "outperform" rating and a $15 price target, suggesting a significant upside of 92.80% from its current price. This aligns with a "Moderate Buy" consensus from other analysts, with seven rating it Buy and two Hold. The biopharmaceutical company also recently surpassed quarterly earnings expectations, reporting higher EPS and revenue than forecast, and institutional investors hold a substantial stake in the company.
Oppenheimer initiates CorMedix stock coverage with outperform rating By Investing.com
Oppenheimer has initiated coverage on CorMedix Inc. (NASDAQ:CRMD) with an Outperform rating and a $15.00 price target, noting the stock is undervalued according to InvestingPro. The firm anticipates strong growth drivers for CorMedix, including resilient utilization of DefenCath, the Melinta portfolio, and potential FDA action for Rezzayo, despite a projected near-term revenue decline for DefenCath. CorMedix's financial health is strong, with more cash than debt and impressive gross profit margins of over 90%, supporting future growth and M&A activities.
CorMedix Inc. (CRMD) Stock Analysis: Biotech Innovator With A 97.69% Potential Upside
CorMedix Inc. (CRMD) shows a promising 97.69% potential upside according to analyst ratings, driven by its flagship product DefenCath and strong revenue growth of 156.50%. Despite its relatively small market cap, the biotech company is focused on combating catheter-related bloodstream infections in kidney dialysis patients. While current technical indicators suggest a mixed short-term outlook, a bullish analyst consensus with an average target price of $15.40 highlights strong confidence in CorMedix's future.
CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Moderate Buy" by Brokerages
CorMedix Inc (NASDAQ:CRMD) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $15.00, significantly higher than its current price of $8.43. The company recently surpassed earnings and revenue expectations, reporting $0.29 EPS and $101.93 million in revenue. Institutional investment in CorMedix has also seen a notable increase, with major firms like BlackRock and Deerfield Management opening new positions.
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD
Bank of New York Mellon Corp has acquired a new position in CorMedix Inc (NASDAQ:CRMD) by purchasing 395,907 shares worth approximately $3.1 million, representing about 0.5% of the company. Other institutional investors also increased their holdings, with a total of 34.18% of the stock owned by hedge funds and institutions. Analysts generally maintain a "Moderate Buy" rating with a consensus price target of $15, especially after CorMedix exceeded quarterly earnings and revenue expectations.
The Technical Signals Behind (CRMD) That Institutions Follow
This article analyzes Cormedix Inc. (NASDAQ: CRMD) using AI models to provide technical signals for institutional trading strategies. It highlights a strong near- and mid-term sentiment that could shift a weak long-term outlook, with specific entry, target, and stop-loss zones for long and short positions across different time horizons. The analysis identifies a mid-channel oscillation pattern and an exceptional short setup targeting 20.8% downside.
243,232 Shares in CorMedix Inc $CRMD Purchased by Empowered Funds LLC
Empowered Funds LLC recently acquired 243,232 shares of CorMedix Inc (NASDAQ:CRMD) worth approximately $1.9 million, representing 0.31% of the company. Other institutional investors also increased their holdings, with institutions and hedge funds collectively owning 34.18% of CRMD. CorMedix reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and analysts maintain a "Moderate Buy" rating with an average target price of $15.00.
Equity award costs paid in stock at CorMedix (CRMD)
CorMedix Chief Legal Officer Beth Zelnick Kaufman disposed of 8,424 shares of common stock on August 29, 2026, in a transaction coded "F." This transaction, valued at $8.30 per share, represents payment for exercise price or tax liability by delivering or withholding securities. Following this, Kaufman directly holds 260,684 shares of CorMedix common stock.
CorMedix (CRMD) COO holds 270K shares after cost-covering share withholding
CorMedix Inc. (CRMD) Chief Operating Officer, Elizabeth Hurlburt, reported a disposal of 8,076 shares of common stock on August 29, 2026. This transaction, coded 'F', was for the payment of exercise price or tax liability by withholding securities. Following this, Hurlburt directly holds 270,463 shares of CorMedix common stock.
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix Therapeutics announced its participation in the Wells Fargo 21st Annual Healthcare Conference. Senior management will engage in a fireside chat and investor meetings in Boston from September 8-10, 2026. A webcast of their fireside chat on September 9th at 12:45 PM EDT will be available, with a replay later accessible on the company's investor relations website.
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix Therapeutics (Nasdaq: CRMD) announced its senior management will participate in the Wells Fargo 21st Annual Healthcare Conference from September 8-10, 2026. The company will host a fireside chat and investor meetings, with a webcast replay available on its investor relations website. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions.
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix Therapeutics (Nasdaq: CRMD) announced its senior management will participate in a fireside chat and investor meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8-10, 2026. The fireside chat is scheduled for Wednesday, September 9, 2026, at 12:45 PM EDT. A replay will be available on the company's investor relations website.
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) is expected to report increased earnings and significantly higher revenues for the quarter ended March 2026, with an earnings release anticipated on May 14. Despite the positive growth outlook, a recent downward revision in the consensus EPS estimate and a negative Earnings ESP make it difficult to conclusively predict an earnings beat. Investors are advised to consider other factors beyond just earnings predictions.
Research Analysts Set Expectations for CorMedix Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for CorMedix (NASDAQ:CRMD) to a loss of $0.05 per share, an improvement from its previous forecast. Analyst sentiment for CorMedix remains largely positive, with a "Moderate Buy" consensus and an average price target of $15. The company recently reported Q3 earnings of $0.29 per share and revenue of $101.93 million, both exceeding consensus estimates.
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade
CorMedix (NASDAQ:CRMD) shares increased by 7.3% following Royal Bank of Canada's upgrade of its price target from $13 to $14, maintaining an "outperform" rating. The company also surpassed its Q2 earnings and revenue estimates, reporting $0.29 EPS against a $0.24 estimate and $101.93 million in revenue compared to a $96.04 million forecast. Analyst sentiment for CRMD remains positive, with a consensus "Moderate Buy" rating and an average price target of $15.
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright
HC Wainwright has increased its FY2026 EPS estimate for CorMedix to $0.54 from $0.51, matching the current analyst consensus. The company recently surpassed quarterly expectations, reporting $0.29 EPS and $101.93 million in revenue. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $15.00 for CorMedix (NASDAQ:CRMD).
(CRMD) as a Liquidity Pulse for Institutional Tactics
Cormedix Inc. (NASDAQ: CRMD) shows a mid-channel oscillation pattern with mixed sentiment across different time horizons. An exceptional short setup is identified with a significant risk-reward ratio. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide institutional tactics.
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating
RBC Capital Markets has increased its price target for CorMedix (CRMD) to $14 from $13, while reiterating an Outperform Speculative Risk rating. This adjustment reflects a positive outlook on the company's financial prospects and potential market performance.
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix Therapeutics (CRMD) reported strong Q2 2026 results, with adjusted earnings and consolidated revenues surpassing analyst estimates, primarily driven by strong DefenCath sales and the contribution from the acquired Melinta portfolio. Following these positive results, management raised its full-year EBITDA outlook. The stock saw a 14.7% increase post-earnings release.
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages
CorMedix Inc (NASDAQ:CRMD) has received an average "Moderate Buy" rating from brokerages, with six out of eight analysts recommending a buy and two recommending a hold. The company's average 12-month price target is $14.86. This follows a strong second quarter where CorMedix beat revenue and earnings expectations, maintained its 2026 revenue outlook, and raised its adjusted EBITDA guidance, driven by a potential supplemental filing for its fungal-disease treatment.
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported strong second-quarter 2026 financial results with $101.9 million in consolidated revenue and $26.0 million in net income, driven by robust sales of DefenCath and contributions from the acquired Melinta portfolio. The company maintained its full-year 2026 revenue guidance and raised its adjusted EBITDA guidance, while also announcing an anticipated FDA submission for an expanded indication of REZZAYO in Q3 2026. These positive results were attributed to strong execution, underlying market demand, and strategic expansion with large dialysis operators.
CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat
CorMedix (NASDAQ:CRMD) shares gapped up after reporting strong quarterly earnings, with EPS of $0.29 beating expectations of $0.24 and revenue of $101.93 million exceeding the $96.04 million consensus. The stock opened at $8.39, up from its previous close of $7.10, and traded around $8.76. Analysts maintain a "Moderate Buy" rating with an average price target of $14.86, and institutional investors have increased their holdings in the company.
CorMedix reports Q2 2026 consolidated revenue $101.9M, net income $26.0M, adjusted EBITDA $58.7M
CorMedix reported strong Q2 2026 financial results with consolidated revenue of $101.9 million, net income of $25.99 million, and adjusted EBITDA of $58.7 million. The company maintained its full-year 2026 revenue guidance and raised its adjusted EBITDA outlook, driven by significant DefenCath sales momentum and contributions from the Melinta portfolio. CorMedix also highlighted progress in regulatory development and commercial expansion, securing a new multi-year supply agreement for DefenCath.
Form 8K CorMedix Inc For: 13 August By Investing.com
This article announces that CorMedix Inc. filed a Form 8K on August 13th, as reported by Investing.com. The brief piece serves as a notification of the SEC filing and provides a direct link to view all comments related to this news.
CorMedix Inc $CRMD Shares Purchased by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. significantly increased its stake in CorMedix Inc. (NASDAQ:CRMD) by 150.6% in the second quarter, now holding 438,629 shares valued at approximately $3.44 million. This increased institutional interest comes as CorMedix reported strong quarterly results, beating EPS and revenue estimates, with its revenue up 226.1% year-over-year. Analysts maintain a "Moderate Buy" consensus for the stock with an average target price of $14.86, notably higher than its opening price of $7.53.
Cormedix Wins Preliminary OK on Governance Settlement Reforms
Cormedix has received preliminary court approval for a proposed settlement in consolidated stockholder derivative actions. This settlement addresses alleged failures to disclose manufacturing deficiencies that delayed FDA approval of DefenCath and negatively impacted the company's stock price. The agreement includes the adoption and maintenance of corporate governance reforms for at least three and a half years, with a final approval hearing scheduled for September 23, 2026.
CorMedix Inc (CRMD) Stock News Today
This article provides an overview of CorMedix Inc (CRMD) stock, including its current price, market capitalization, and P/E ratio. It indicates that further news, earnings reports, analyst ratings, and key developments related to the company will be available soon. The page serves as a hub for financial information and updates on CRMD.
CorMedix receives preliminary court approval for derivative lawsuit settlement
CorMedix Inc. announced that a U.S. District Court has granted preliminary approval for the settlement of a consolidated shareholder derivative lawsuit. A final settlement hearing is scheduled for September 23, 2026. The company also recently reported strong Q1 2026 earnings and upheld a patent victory against Nexus Pharmaceuticals.
Earnings Preview: CorMedix to Report Financial Results Pre-market on August 13
This article announces that CorMedix (CRMD) is scheduled to report its financial results pre-market on August 13. Investors will be keen to see if the company met expectations, with analysts forecasting a loss of $0.06 per share and revenues of $0.46 million. The report will likely influence the stock's performance following a recent 16.5% decline.
Form 8K CorMedix Inc For: 7 August By Investing.com
This article reports on CorMedix Inc.'s (CRMD) filing of a Form 8K on August 7. The filing is a standard SEC document used by companies to announce unscheduled material events or corporate changes that shareholders should know about. The brief piece indicates that Investing.com is the source of this financial markets news.
CorMedix secures preliminary court approval for derivative settlement, to adopt governance reforms
CorMedix has received preliminary court approval for a proposed derivative settlement which includes the implementation of corporate governance reforms for at least 3.5 years. A final hearing is scheduled for September 23, 2026. The settlement does not provide a monetary fund for stockholders, and plaintiffs' counsel will seek up to $3.9 million in attorneys' fees, which defendants reserve the right to oppose.
Pacer Advisors Inc. Purchases 326,724 Shares of CorMedix Inc $CRMD
Pacer Advisors Inc. significantly increased its stake in CorMedix Inc. by 128.7% in the first quarter, acquiring an additional 326,724 shares to hold a total of 580,620 shares valued at $3.94 million. Institutional investors now collectively own 34.18% of CRMD, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $14.86. The company recently reported strong quarterly earnings, beating EPS estimates and showing a substantial year-over-year revenue increase of 226.1%.
Empowered Funds LLC Grows Position in CorMedix Inc $CRMD
Empowered Funds LLC significantly increased its stake in CorMedix Inc (NASDAQ:CRMD) by 102.1% in the first quarter, now owning 266,637 shares valued at $1.81 million. Institutional investors collectively hold 34.18% of Cor
(CRMD) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Cormedix Inc. (NASDAQ: CRMD), highlighting strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 89.0:1 risk-reward setup, targeting a 27.1% gain versus a 0.3% risk. The analysis includes three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and a multi-timeframe signal analysis for CRMD.
CorMedix Inc (CRMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CorMedix Inc (CRMD), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, CRMD's price momentum score is 4.15, and the stock is trading between a resistance level of $8.63 and a support level of $6.78, suggesting suitability for range-bound swing trading. The analysis includes a breakdown of indicators like MACD, RSI, and KDJ, as well as multiple moving averages, with a summary indicating a "Neutral" signal based on these metrics.
